TY - JOUR
T1 - Zoledronic acid
T2 - Multiplicity of use across the cancer continuum
AU - Lipton, Allan
N1 - Funding Information:
Dr Lipton has participated as a consultant for Amgen, Centocor Ortho Biotech, Novartis and Thar Pharmaceuticals; has received honoraria from Amgen, Centocor Ortho Biotech and Novartis; and has received research funding from the Pennsylvania Breast Cancer Coalition, Monogram Biosciences and Novartis. Dr Lipton has given expert testimony for Novartis. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2011/7
Y1 - 2011/7
N2 - Zoledronic acid (ZOL) has proven efficacy for reducing the risk of skeletal-related events in patients with bone metastases from a broad range of solid tumors and bone lesions from multiple myeloma. In a head-to-head trial in patients with breast cancer, ZOL demonstrated efficacy at least comparable with, and some benefits beyond those of, pamidronate. Several studies have also demonstrated additional benefits from ZOL, including preventing bone loss, and potential anticancer activity. Adding ZOL to anticancer therapy improved disease-free and overall survival in clinical trials in women receiving adjuvant endocrine therapy for breast cancer and in patients with newly diagnosed multiple myeloma. Thus, recent advances suggest that, in addition to its established role in reducing skeletal morbidity, ZOL might also help preserve bone health in patients with early stage breast cancer. The potential role of ZOL as an anticancer therapy in this setting is the focus of intense investigation and awaits insights from ongoing clinical trials.
AB - Zoledronic acid (ZOL) has proven efficacy for reducing the risk of skeletal-related events in patients with bone metastases from a broad range of solid tumors and bone lesions from multiple myeloma. In a head-to-head trial in patients with breast cancer, ZOL demonstrated efficacy at least comparable with, and some benefits beyond those of, pamidronate. Several studies have also demonstrated additional benefits from ZOL, including preventing bone loss, and potential anticancer activity. Adding ZOL to anticancer therapy improved disease-free and overall survival in clinical trials in women receiving adjuvant endocrine therapy for breast cancer and in patients with newly diagnosed multiple myeloma. Thus, recent advances suggest that, in addition to its established role in reducing skeletal morbidity, ZOL might also help preserve bone health in patients with early stage breast cancer. The potential role of ZOL as an anticancer therapy in this setting is the focus of intense investigation and awaits insights from ongoing clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=79961035423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79961035423&partnerID=8YFLogxK
U2 - 10.1586/era.11.71
DO - 10.1586/era.11.71
M3 - Article
C2 - 21806323
AN - SCOPUS:79961035423
SN - 1473-7140
VL - 11
SP - 1001
EP - 1014
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
IS - 7
ER -
